This company has been marked as potentially delisted and may not be actively trading. Lionheart Acquisition Co. II (LCAP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock LCAP vs. AORT, PINC, ARQT, CGON, ACHC, ANIP, ADPT, VCEL, ARDT, and CERTShould you be buying Lionheart Acquisition Co. II stock or one of its competitors? The main competitors of Lionheart Acquisition Co. II include Artivion (AORT), Premier (PINC), Arcutis Biotherapeutics (ARQT), CG Oncology (CGON), Acadia Healthcare (ACHC), ANI Pharmaceuticals (ANIP), Adaptive Biotechnologies (ADPT), Vericel (VCEL), Ardent Health (ARDT), and Certara (CERT). These companies are all part of the "medical" sector. Lionheart Acquisition Co. II vs. Its Competitors Artivion Premier Arcutis Biotherapeutics CG Oncology Acadia Healthcare ANI Pharmaceuticals Adaptive Biotechnologies Vericel Ardent Health Certara Lionheart Acquisition Co. II (NASDAQ:LCAP) and Artivion (NYSE:AORT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations. Is LCAP or AORT more profitable? Lionheart Acquisition Co. II has a net margin of 0.00% compared to Artivion's net margin of -4.43%. Artivion's return on equity of 5.70% beat Lionheart Acquisition Co. II's return on equity.Company Net Margins Return on Equity Return on Assets Lionheart Acquisition Co. IIN/A -44.30% 1.39% Artivion -4.43%5.70%2.29% Do analysts recommend LCAP or AORT? Artivion has a consensus target price of $40.63, suggesting a potential downside of 9.33%. Given Artivion's stronger consensus rating and higher possible upside, analysts plainly believe Artivion is more favorable than Lionheart Acquisition Co. II.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lionheart Acquisition Co. II 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Artivion 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do institutionals and insiders hold more shares of LCAP or AORT? 86.4% of Artivion shares are owned by institutional investors. 19.4% of Lionheart Acquisition Co. II shares are owned by insiders. Comparatively, 7.6% of Artivion shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has preferable valuation and earnings, LCAP or AORT? Lionheart Acquisition Co. II has higher earnings, but lower revenue than Artivion. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLionheart Acquisition Co. IIN/AN/A$3.21MN/AN/AArtivion$388.54M5.44-$13.36M-$0.42-106.70 Does the media refer more to LCAP or AORT? In the previous week, Artivion had 10 more articles in the media than Lionheart Acquisition Co. II. MarketBeat recorded 10 mentions for Artivion and 0 mentions for Lionheart Acquisition Co. II. Artivion's average media sentiment score of 0.89 beat Lionheart Acquisition Co. II's score of 0.00 indicating that Artivion is being referred to more favorably in the news media. Company Overall Sentiment Lionheart Acquisition Co. II Neutral Artivion Positive Which has more volatility and risk, LCAP or AORT? Lionheart Acquisition Co. II has a beta of 0.08, suggesting that its share price is 92% less volatile than the S&P 500. Comparatively, Artivion has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500. SummaryArtivion beats Lionheart Acquisition Co. II on 11 of the 14 factors compared between the two stocks. Get Lionheart Acquisition Co. II News Delivered to You Automatically Sign up to receive the latest news and ratings for LCAP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LCAP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LCAP vs. The Competition Export to ExcelMetricLionheart Acquisition Co. IIBusiness Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$511.85M$137.93M$5.81B$9.76BDividend YieldN/AN/A4.39%4.06%P/E RatioN/A0.5631.3626.05Price / SalesN/A21.66387.8788.42Price / Cash20.6411.7038.0259.36Price / Book-9.733.329.536.60Net Income$3.21M$1.30M$3.26B$265.65M Lionheart Acquisition Co. II Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LCAPLionheart Acquisition Co. IIN/A$27.74+1.0%N/A+10,134.8%$511.85MN/A0.003AORTArtivion3.5694 of 5 stars$42.01-2.0%$39.80-5.3%+70.9%$2.02B$388.54M-100.031,600News CoverageAnalyst ForecastInsider TradePINCPremier2.3381 of 5 stars$26.21+7.3%$22.57-13.9%+22.6%$2.01B$1.35B45.982,900Trending NewsDividend AnnouncementAnalyst ForecastHigh Trading VolumeARQTArcutis Biotherapeutics1.7925 of 5 stars$15.77-5.8%$19.80+25.6%+62.6%$2.01B$263.47M-21.03150News CoveragePositive NewsCGONCG Oncology1.3761 of 5 stars$25.56-2.2%$55.27+116.2%-27.3%$1.99B$551K-14.4461ACHCAcadia Healthcare4.7425 of 5 stars$21.59+2.2%$40.77+88.9%-71.9%$1.95B$3.15B14.3025,500Analyst RevisionANIPANI Pharmaceuticals3.2796 of 5 stars$90.12+0.5%$84.75-6.0%+47.6%$1.95B$614.38M-117.04600News CoverageAnalyst UpgradeInsider TradeADPTAdaptive Biotechnologies2.4049 of 5 stars$12.56+1.2%$12.38-1.5%+167.5%$1.89B$178.96M-15.32790News CoverageAnalyst RevisionVCELVericel2.4884 of 5 stars$36.17-0.4%$60.33+66.8%-24.9%$1.83B$237.22M301.44300Positive NewsARDTArdent Health3.3609 of 5 stars$12.94+2.5%$19.56+51.2%-25.1%$1.81B$5.97B7.1524,900CERTCertara4.3947 of 5 stars$11.02-1.4%$15.14+37.4%-13.7%$1.80B$405.76M220.441,546News CoveragePositive News Related Companies and Tools Related Companies AORT Alternatives PINC Alternatives ARQT Alternatives CGON Alternatives ACHC Alternatives ANIP Alternatives ADPT Alternatives VCEL Alternatives ARDT Alternatives CERT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LCAP) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lionheart Acquisition Co. II Please log in to your account or sign up in order to add this asset to your watchlist. Share Lionheart Acquisition Co. II With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access